Clinical Therapeutic Intelligence Report: 2015 Year in Review
|
|
- Gerard Simpson
- 5 years ago
- Views:
Transcription
1 Clinical Therapeutic Intelligence Report: 2015 Year in Review This issue highlights the many ground-breaking therapies approved by the U.S. Food and Drug Administration over the course of Highlights include immunotherapies, new treatment options for breast cancer patients, and financial assistance options for cancer patients. Breakthrough therapies for blood, lung and skin cancers dominated 2015 oncology approvals. There were 17 new oral and infusion approvals, with 10 expanded indications for drugs approved prior to 2015*. Only eight new drugs and one expanded indication were approved in 2014, representing a 200 percent increase in just one year. Immunotherapies swept the approvals, with s nivolumab and Merck Oncology s pembrolizumab, previously approved for melanoma, adding indications for non-small cell lung cancer and renal cell carcinoma over the course of the year really established a new line of therapy for, essentially, the vast majority of non-small cell lung cancer patients, and that was immunotherapy, said Dr. Mark Socinski, Director of the Lung Cancer Section of the Divison of Hematology/Oncology at the University of Pittsburgh School of Medicine. These approvals created choices, and from that perspective, 2015 was a monumental year. Of 50 oncologists surveyed by MedPage Today, 37 cited immunotherapy drugs as game-changers in 2015 i. Checkpoint s spread into new tumor types heralded new thinking about ways in which certain cancers can be treated, while also showing promise for more difficult types of cancers. AstraZeneca s osimertinib, approved for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer, has also garnered attention in the oncology space. Oncologists are optimistic about its benefit for patients, despite the relatively small patient population ii. Osimertinib is the first of it s kind, the issue is that it s a much smaller patient population, said Socinski. Palbociclib, developed by Pfizer,, was granted accelerated approval in February for postmenopausal women with ER+/ HER2- advanced breast cancer, the largest subgroup of breast cancer cases iii. Palbociclib targets a family of proteins responsible for cell growth, and is the first new first-line therapy for this patient population in 10 years. Other key approvals include s panobinostat and Takeda Oncology s ixazomib, both approved for the treatment of multiple myeloma. Approved for advanced colorectal cancer, trifluiridine/tipiracil is a new treatment option for patients who no longer responded to other therapies developed by Taiho Oncology. * Biosimilars have not been included See full list of oncology drug approvals on pages 3-4.
2 A look ahead: the 2016 pipeline According to the Pharmaceutical Research and Manufacturers of America (PhRMA), of the 771 new drugs and vaccines in the development pipeline, 98 are being developed for lung cancer, 87 for leukemia, 78 for lymphoma, 73 for breast cancer, 56 for skin cancer, and 48 for ovarian cancer iv. A noteworthy drug in the pipeline is AbbVie s venetoclax, an of the b-cell lymphoma-2 (bcl-2) protein, that has received two Breakthrough Therapy designations v. The FDA has recently granted Breakthrough Therapy designation to venetoclax in combination with rituximab for patients with relapsed/refractory Chronic Lymphocytic Leukemia. In a Phase 1b study, it has been reported that 41 percent (20 of 49 patients) have acheived either a complete response or complete response with incomplete marrow recovery. Eighty-four percent of patients acheived an objective response to the treatment vi. In April 2015, the FDA granted Breakthrough Therapy designation to single agent venetoclax for the treatment of patients with relapsed/refractory Chronic Lymphocytic Leukemia with the 17p deletion genetic mutation. This single agent application was also granted Priority Review. Roche s PD-L1 checkpoint, atezolizumab, is already causing excitement among oncologists vii. At the 2015 European Cancer Congress, Roche investigators reported atezolizumab showed a 7.7-month survival advantage over chemotherapy for lung cancer patients with a significant expression of PD-L1. Twenty-seven percent of the same type of patients saw tumors shrink, while in another trial, 27 perecent of bladder cancer patients with significant PD-L1 expression responded to atezolizumab. According to Roche s chief of global product development, these results represent the first major treatment advancement for advanced bladder cancer patients in nearly 30 years. Financial assistance for oncology therapies Many cancer patients experience financial hardships during treatment. Even with insurance, the copay and out-ofpocket costs for medications is often hard to manage. Due to this financial strain, an estimated 10 to 20 percent of patients do not take or otherwise compromise their treatment viii. Often, the greater the out-of-pocket cost for the oral cancer therapy, the lower the compliance. The main forms of assistance available for medication costs are foundations and manufacturer assistance programs. Foundation Assistance Most foundations only offer copay assistance programs; the full price of the drug will not be covered ix. For insured patients with high out-of-pocket copays, foundation Biologics, assistance programs will be able to help with that cost. Foundations have different assistance programs 120 for Weston various Oaks disease Court states, so patients must apply to the specific program within the foundation. Depending on Cary, the time NC of year, funding is not always available. Requirements for receiving financial assistance vary across foundations, but most programs have an income limitation of percent of the Federal Poverty Guidelines, and some consider the cost of living index. Manufacturer Assistance Programs Assistance programs for patients without insurance are run by the manufacturer of the drug. The majority of these programs provide free drug to eligible patients for a specified amount of time, with the option to reapply. Similar to foundations, these programs have income limitations of percent of the Federal Poverty Guidelines. Eligibility for Manufacturer Assistance Programs is often restricted to patients without insurance, or with Medicare Part D benefits or insurance plans that do not cover any of their medication. Applying for Assistance Some organizations will let healthcare providers complete all or most of the application process on behalf of the patient. While the application process varies across programs, patient and prescriber contact information, proof of income, prescription information, medical history and insurance coverage is often required.
3 2015 Drug Approval Breakdown Drug Name Manufacturer Indication Genetics Route of Administration Mechanism Clinical Trial Results Biologics Availability IMBRUVICA (ibrutinib) Janssen Waldenström s macroglobulinemia (WM) N/A PO BTK 62% of patients had cancer shrink for (WM) IBRANCE (palbociclib) Pfizer, ER-positive, HER2-negative advanced breast cancer ER, HER2 PO CDK4/ of progression free survival, compared to 10.2 LENVIMA (lenvatinib) Eisai, Radioactive iodine-refractory differentiated thyroid cancer N/A PO Multi-kinase Median of 18.3 of progression free survival, compared to median of 3.6 FARYDAK (panobinostat) vartis Multiple myeloma N/A PO HDAC 10.6 of progression-free survival, compared to 5.8 Metastatic squamous non-small cell lung cancer BRAF IV PD-1 blocking 15% experienced objective response rate, 59% had response durations of 6 or longer UNITUXIN (dinutuximab) United Therapeutics Pediatric high-risk neuroblastoma N/A IV GD2-binding monoclonal Three year estimate of overall survival was 80%, compared to 67% CYRAMZA (ramucirumab) Eli Lilly and Company Metastatic colorectal cancer (mcrc) VEGFR2 IV VEGFR2 antagonist Median overall surival was 13.3, compared to 11.7 with placebo IRESSA (gefitinib) AstraZeneca Metastatic non-small cell lung cancer EGFR mutationpositive PO EGFR 70% overall response rate, with a median duration of response of 8.3 ODOMZO (sonidegib) vartis Locally advanced basal cell carcinoma N/A PO Hedgehog signaling pathway 58% overall response rate, with a duration of 1.9 to 18.6 Kyprolis (carfilzomib) Onyx, Multiple myeloma N/A IV Proteasome 22.9% overall response rate, with a median duration of 7.8 ADCETRIS (brentuximab vedotin) Seattle Genetics Classical Hodgkin lymphoma, Systemic anaplastic large cell lymphoma N/A IV CD30-directed -drug conjugate 73% of patients achieved either a complete or partial response to treatment, responses lasted on average 6.7 LONSURF (trifluridine/ tipiracil) Taiho Oncology, Metastatic colorectal cancer N/A PO Nucleoside metabolic, thymidine phosphorylase Median overall survival lasted an average of 7.1 compared to 5.3 In combination with ipilimumab for BRAF V600 wild-type, unresectable or metastatic melanoma BRAF IV PD-1 blocking Overall response rate of 60% in nivolumab plus ipilimumab group, compared to 11% in ipilimumab group, an improvement in ORR of 49%
4 2015 Drug Approval Breakdown Drug Name Manufacturer Indication Genetics Route of Administration Mechanism Clinical Trial Results Biologics Availability KEYTRUDA (pembrolizumab) Merck Sharp and Dohme Metastatic non-small cell lung cancer Tumors shrank in 41% of patients, and effect lasted between 2.1 and 9.1 Metastatic non-squamous nonsmall cell lung cancer Overall survival of 12.2, compared to 9.4 in patients treated with docetaxel ONIVYDE (irinotecan liposome injection) Merrimack, Metastatic adenocarcinoma of the pancreas N/A IV Topoisomerase Median overall survival of 6.1 for patients who received irinotecan liposome in combination with 5FU and LV YONDELIS (trabectedin) Janssen Biotech liposarcoma or leiomyosarcoma N/A IV Alkylating drug Median overall survival lasted 13.7, with median progression free survival of 4.2 YERVOY (ipilimumab) COTELLIC (cobimetinib) TAGRISSO (osimertinib) DARZALEX (daratumumab injection) NINLARO (ixazomib) MEKINIST (trametinib) TAFINLAR (dabrafenib) Cutaneous melanoma N/A IV CTLA-4-blocking Genentech, AstraZeneca melanoma Metastatic EGFR T790M-positive non-small cell lung cancer Median recurrence-free survival of 26 BRAF PO MEK Median progression free survival of 12.3 EGFR PO EGFR-TKI Two studies showed overall response rates of 57% and 61%, respectively Jannsen Biotech Multiple myeloma N/A IV Human CD38- directed monoclonal Takeda vartis Multiple myeloma N/A PO Proteasome BRAF-mutated melanoma BRAF PO MEK1/2, BRAF Objective response rate of 29% with a median response duration of 7.4 Median progression free survival of 20.6, compared to 14.7 Overall survival of 25.1 in combination, compared to 18.7 compared to dabrafenib monotherapy PORTRAZZA (necitumumab) EMPLICITI (elotuzumab) ALECENSA (alectinib) KEYTRUDA (pembrolizumab) Advanced renal cell carcinoma N/A IV PD-1 blocking Eli Lilly and Company Metastatic squamous non-small cell lung cancer Median overall survival of 25, with a median response duration of 23 N/A IV EGFR antagonist Median overall survival of 11.5, with median progression free survival of 5.7 Multiple myeloma SLAMF7 IV SLAMF7-directed immunostimulatory Hoffmann-La Roche, Merck Sharp and Dohme ALK+ metastatic non-small cell lung cancer melanoma (First-Line therapy) Median progression free survival of 19.4, with an overall response rate of 78.5% ALK PO ALK 44% of patients experienced tumor shrinkage, effect lasted for an average of 7.5 Median progression free survival of 5.5 and 4.2 for pembrolizumab, compared to 2.8 for ipilimumab
5 Sources: i Immunotherapy Is Game-Changer for Oncology, Roger Sergel. December 27, ii FDA Updates: Oncology, Surabhi Dani-Garimella, PhD, December 16, iii FDA approves groundbreaking new drug, Ibrance, for patients with estrogen-receptor positive advance breast cancer, Science Daily, February 3, iv The 2015 Oncology Drug Pipeline: Innovation Drives the Race to Cure Cancer, American Health & Drug Benefits, June v AbbVie s venetoclax receives Breakthrough Therapy designation from FDA in combination with rituximab for the treatment of patients with relapsed/refractory Chronic Lymphocytic Leukemia, AbbVie, January 20, vi For Refractory CLL, Venetoclax s Complete Response Rate Is Tops, Medscape, June 15, vii Roche wins kudos for game-changing atezolizumab cancer data, FierceBiotech, September 28, viii In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs, Mayo Clinic Proceedings, July 23, ix Financial Assistance for Oncology Therapies, Biologics, vember 5, More Information To sign up to receive additional information about the Oncology Pipeline, please info@biologicsinc.com. Contact Us Phone: info@biologicsinc.com biologicsinc.com Biologics, 120 Weston Oaks Court Cary, NC Connect with us on LinkedIn, just search for Biologics, Like us on Facebook, just search for Biologics, Follow us on Twitter, we Copyright Biologics, All rights reserved.
PRECISION CANCER MEDICINE DR. VANESSA DICKEY TORRANCE MEMORIAL PHYSICIAN NETWORK CANCER CARE ASSOCIATES
PRECISION CANCER MEDICINE DR. VANESSA DICKEY TORRANCE MEMORIAL PHYSICIAN NETWORK CANCER CARE ASSOCIATES REAL PATIENT; ANN (ALIAS) 63 year old woman who smoked for 25 years, quit 15 years ago. Complained
More informationNew Cancer Drug Update 2015/2016. Teresa Knoop, MSN, RN, AOCN Vanderbilt-Ingram Cancer Center Nashville, TN
New Cancer Drug Update 2015/2016 Teresa Knoop, MSN, RN, AOCN Vanderbilt-Ingram Cancer Center Nashville, TN Disclosures No conflicts to disclose Objectives Identify new drugs that were FDA approved for
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda
More informationOral Chemotherapy Agents
Oral Chemotherapy Agents NEW ADVANCES IN TARGETED THERAPY, OVERCOMING BARRIERS AND PROMOTING ADHERENCE KATIE SIAS, PHARMD CLINICAL PHARMACY COORDINATOR HEMATOLOGY/ONCOLOGY MIDMICHIGAN MEDICAL CENTER -
More informationGoals & Objectives. Disclosure. Abbreviations. New and Emerging Chemotherapies 3/2/ Author has nothing to disclose
Goals & Objectives New and Emerging Chemotherapies Luis Hernandez PGY-1 Pharmacy Resident University of Miami Hospital www.fshp.org Distinguish key differences between new oral and parenteral chemotherapies
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More informationCompassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018
Compassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018 Het CBG kan in schrijnende gevallen toestemming verlenen voor het in de handel brengen van een geneesmiddel
More informationClinical Therapeutic Intelligence Report: Year in Review
Clinical Therapeutic Intelligence Report: Year in Review Last year marked a productive year for oncology drug research and development with ten new oncology drugs coming to market two of which were granted
More informationUpdates in Hematology
Updates in Hematology Disclosure Received honoraria on Speaker s Bureau for Pfizer and Takeda Oncology Received honoraria for Advisory Board of Pfizer and Lilly Manpreet Chahal, PharmD, PhD Oncology Pharmacist,
More information2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO
2016 Updates in Oncology & Malignant Hematology Brendan Curley, DO Disclosures I received final support from ASCO Conquer Cancer foundation in two Merit Awards and one travel award I am on the speakers
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 5 Last Review Date: June 24, 2016 Keytruda Description Keytruda (pembrolizumab)
More informationNew Developments in Cancer Treatment. Dulcinea Quintana, MD
New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4
More informationSpecialty Pipeline Update
CLINICAL SOLUTIONS Drug Insights > December 2015 Specialty Pipeline Update New Drug Information Alecensa (alectinib): The Food and Drug Administration (FDA) approved Genentech s orally administered ALK
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationGlobal Oncology Trends 2017
June 2017 Global Oncology Trends 2017 Advances, Complexity and Cost $ Introduction Over the past decade, there has been a paradigm shift in the treatment of cancer, driven by advances in personalized medicine
More informationFirst phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress
Media Release Basel, 03 October 2016 First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Superiority results from the phase
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationDrug Prior Authorization Form Opdivo (nivolumab)
This document contains both information and form fields. To read information, use the Down Arrow from a form field. Drug Prior Authorization Form The purpose of this form is to obtain information required
More informationRoche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting
Media Release Basel, 5 November 2015 Roche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting Gazyva/Gazyvaro (obinutuzumab) and investigational
More informationKeytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
More informationGENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)
CANCER (NSCLC) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
More informationCancer Researchers Report Longer Survival Rates With Immunotherapy
http://nyti.ms/1jlz74z HEALTH NYT NOW Cancer Researchers Report Longer Survival Rates With Immunotherapy By ANDREW POLLACK JUNE 2, 2014 CHICAGO Drugs that unleash the body s immune system to combat tumors
More informationTo register or to learn more please visit:
A Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers When Saturday, October 29, 2016 8:00 AM to 4:00 PM Where JW Marriott
More informationLEVERAGING FDA S ACCELERATED PATHWAYS FOR MARKET ADVANTAGE
WHITE PAPER LEVERAGING FDA S ACCELERATED PATHWAYS FOR MARKET ADVANTAGE Over the past 15 years, the FDA and Congress developed several accelerated pathways to provide incentives for manufacturers to develop
More informationNCCN Non Small Cell Lung Cancer V Meeting July 8, 2016
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
More informationRole of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
More informationOpen and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
More informationTARGETED THERAPY FOR LUNG CANCER. Patient and Caregiver Guide
TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Why Targeted Therapy?...2 Lung Cancer Basics...2 Changes in
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationClinical Trial News on the Treatment of Waldenstrom s Macroglobulinemia
Clinical Trial News on the Treatment of Waldenstrom s Macroglobulinemia Edward Libby M.D. Associate Professor, University of Washington Department of Medicine, Division of Medical Oncology Fred Hutchinson
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More information04 September 2017 Page 1 of 6
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
More informationCancer Drug Pipeline Information for Patient Advocacy Groups. Breast Cancer. Route of Administration. Brand Name Generic Name Manufacturer Indication
Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the will be submitted to the pcodr program. The use of this information is solely intended for informational
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 28 th Prioritization 3 rd quarter 2016 General Information, efficacy and safety data Nicole Grössmann Claudia Wild Please note: Within this document
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:
Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationInvestor Update. Basel, 10 May 2018
Investor Update Basel, 10 May 2018 Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal
More informationMICROSCOPY PREDICTIVE PROFILING
Immunomodulatory therapy in NSCLC: a year into clinical practice Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor to and speaker
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationMedia Release. Basel, 12 December 2017
Media Release Basel, 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of
More informationCyramza. Cyramza (ramucirumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.44 Subject: Cyramza Page: 1 of 6 Last Review Date: September 15, 2017 Cyramza Description Cyramza
More informationREFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical
More informationORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationMerck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference
Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More informationCancer Therapy Update in 2017
Cancer Therapy Update in 2017 Editor: Le Wang, M.D., Ph.D Medical Oncology and Hematology (Board-Certified) Ibrutinib (Imbruvica) Pharmacyclics 1 /19/2017 Lymphoma Marginal Zone Lymphoma (MZL), Relapsed/Refractory
More informationMedia Release. Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Media Release Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia Approval is based on randomised phase III MURANO study showing that
More informationCancer Across the Lifespan: Focus on Supportive Care
Cancer Across the Lifespan: Focus on Supportive Care Traci M. White, PharmD, PhC Assistant Professor UNM College of Pharmacy Pharmacist Clinician Mesilla Valley Hospice tmwhite@nmsu.edu Objectives Identify
More informationOncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationNew Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
More informationPersonalized Therapies for Lung Cancer. Questions & Answers
Personalized Therapies for Lung Cancer Questions & Answers What are Personalized Therapies for lung cancer? Like people, no two lung cancer tumors are the same. Personalized medicine (also known as precision
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More information29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
More informationOpening Address: A Quick Survey Thinking 25 Years Backwards & Forwards
Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 27 th Prioritization 2 nd quarter 2016 General Information, efficacy and safety data Nicole Grössmann Claudia Wild Please note: Within this document
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationSpecialty Pipeline Update
Specialty Pipeline Update D Drug Insights > March 2016 New drug information Odefsey (emtricitabine, tenofovir alafenamide, rilpivirine): The Food and Drug Administration (FDA) approved Gilead s combination
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationCorporate Medical Policy
Corporate Medical Policy BRAF Gene Variant Testing to Select Melanoma or Glioma Patients File Name: Origination: Last CAP Review: Next CAP Review: Last Review: braf_gene_variant_testing_to_select_melanoma_or_glioma_patients_for_targeted_
More informationErbitux. Erbitux (cetuximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)
More informationRoche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia
Media Release Basel, 12 April 2016 Roche announces FDA grants Venclexta(venetoclax) accelerated approval for people with hard-to-treat type of chronic lymphocytic leukemia Venclexta is designed to help
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationLung Cancer Update 2016 BAONS Oncology Care Update
Lung Cancer Update 2016 BAONS Oncology Care Update Matthew Gubens, MD, MS Assistant Professor Chair, Thoracic Oncology Site Committee UCSF Helen Diller Family Comprehensive Cancer Center Disclosures Consulting
More informationCyramza. Cyramza (ramucirumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.44 Subject: Cyramza Page: 1 of 6 Last Review Date: June 24, 2016 Cyramza Description Cyramza (ramucirumab)
More informationPharmacy Medical Necessity Guidelines: Oral Cancer Medications
Pharmacy Medical Necessity Guidelines: Effective: February 18, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationLung Cancer Patient Survey
Lung Cancer Patient Survey Registered User Who is filling out the lung cancer questionnaire? The patient (person diagnosed with lung cancer) Spouse Parent Legal guardian Other relative Other non-relative
More informationImmunotherapy and Targeted Therapies: The new face of cancer treatment
Immunotherapy and Targeted Therapies: The new face of cancer treatment Abdulazeez Salawu MBBS, MSc, PhD, MRCP Academic Clinical Lecturer Weston Park Hospital, Sheffield Novel Systemic Anti-cancer Therapies
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC
Clinical Policy: (Opdivo) Reference Number: CP.HNMC.27 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 07.01.18 Last Review Date: 11.17 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the
More informationInnovations in Immunotherapy - Melanoma. Systemic Therapies October 27, 2018 Charles L. Bane, MD
Innovations in Immunotherapy - Melanoma Systemic Therapies October 27, 2018 Charles L. Bane, MD Melanoma Prognosis Survival at 10 years Stage I: 90% Stage II: 60% Stage III: 40% Stage IV: 10% 2 Indications
More informationREFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Vectibix for colorectal cancer (CRC) in the eight major
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationREFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Stivarga for colorectal cancer (CRC) in the eight major
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Patrick Medina, Pharm.D., BCOP Professor The University of Oklahoma College of Medicine Stephenson Cancer Center Faculty Disclosure
More informationClinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322
Clinical Policy: (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 03/17 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationImmunotherapy and Lung Cancer
Immunotherapy and Lung Cancer This booklet explains how immunotherapy uses the body s own natural defenses to treat lung cancer. So far, immunotherapy is approved for non-small cell lung cancer (NSCLC)
More informationDRUG TRIALS SNAPSHOTS. Milena Lolic, MD, MS Medical Officer Professional Affairs and Stakeholder Engagement CDER/FDA
DRUG TRIALS SNAPSHOTS Milena Lolic, MD, MS Medical Officer Professional Affairs and Stakeholder Engagement CDER/FDA 1 Presentation Outline FDASIA 907 Overview What are Drug Trials Snapshots? Where to find
More information